The United States has some of the lowest prices in the world for most drugs. The U.S. generic drug market is competitive and robust—but its success is not accidental. It is the result of a series of deliberate, well-designed policy interventions. The 1984 Hatch-Waxman Act allowed generic drug manufacturers to bypass costly safety and efficacy […]
How America Built the World’s Most Successful Market for Generic Drugs
How America Built the World’s Most Successful Market for Generic Drugs
06 Jun 2025 1 Comment
in applied price theory, economics of regulation, entrepreneurship, health economics, industrial organisation Tags: drug lags
New medicine approvals plan an exercise in not solving the problem
28 May 2025 Leave a comment
in applied price theory, economics of bureaucracy, economics of regulation, health economics, politics - New Zealand, Public Choice Tags: drug lags
Eric Crampton writes – New medicines are slow to be authorised for the New Zealand market. Even if a medicine has already been approved by many other trustworthy overseas regulators like those in Canada, the UK, Australia, and the EU, Medsafe can take a very long time to evaluate a medicine.
New medicine approvals plan an exercise in not solving the problem
‘Rule of Two’ medicines approval needs improving
28 Apr 2025 Leave a comment
in applied price theory, economics of bureaucracy, economics of regulation, health economics, politics - New Zealand, Public Choice Tags: drug lags
Eric Crampton writes – Come the next pandemic, we are going to be in the same stupid mess that we were in during the last one. Trusted pharmaceutical regulators overseas, like those in Australia, Canada, Europe, and the UK, will have given provisional approvals for vaccines that are safe. And Kiwis will have to wait, […]
‘Rule of Two’ medicines approval needs improving
Hire Don’t Fire at the FDA
26 Feb 2025 Leave a comment
in applied price theory, comparative institutional analysis, economics of regulation, health economics, politics - USA Tags: 2024 presidential election, drug lags
As a longtime critic of the FDA, you might expect me to support firing FDA employees—not so! My focus has always been on reducing approval time and costs to speed drugs to patients and increase the number of new drugs. Cutting staff is more likely to slow approvals and raise costs. To be fair, we’re […]
Hire Don’t Fire at the FDA
Milei Implements Peer Approval for Food
24 Jan 2025 Leave a comment
in applied price theory, development economics, economics of regulation, health economics, politics - Australia, politics - New Zealand, politics - USA Tags: drug lags, food safety
Reason: In a sweeping move to overhaul Argentina’s food trade policies, Javier Milei’s administration officially deregulated food imports and exports on Monday. The reform, outlined in Decree 35/2025, seeks to boost foreign trade, cut bureaucratic red tape, and lower consumer prices. Federico Sturzenegger, head of the Ministry of Deregulation and State Transformation, explained in a post on […]
Milei Implements Peer Approval for Food
The New FDA and the Regulation of Laboratory Developed Tests
28 Dec 2024 Leave a comment
in applied price theory, economics of bureaucracy, economics of regulation, health economics, politics - USA, Public Choice Tags: drug lags
The FDA under President Trump and new FDA head Martin Makary should rapidly reverse the FDA’s powergrab on laboratory developed tests. To recap, laboratory developed tests (LDTs) are the kind your doctor orders, they are a service not a product and are not sold directly to patients. Congress has never given the FDA the authority […]
The New FDA and the Regulation of Laboratory Developed Tests
Biden-Harris policies and their consequences were no surprise to those paying attention
30 Oct 2024 Leave a comment
in applied price theory, applied welfare economics, budget deficits, business cycles, econometerics, economic growth, economic history, economics of bureaucracy, economics of regulation, energy economics, entrepreneurship, environmental economics, financial economics, fiscal policy, global warming, health economics, income redistribution, industrial organisation, law and economics, macroeconomics, monetary economics, politics - USA, property rights, Public Choice, public economics, rentseeking Tags: 2024 presidential election, drug lags, taxation and entrepreneurship, taxation and investment
Milton Friedman used to advise researchers to focus on large policy changes rather than attempting to separate a small change’s signal from the noise. In this sense, the “ambitious” policy agenda of the Biden-Harris administration was expected to be a gift to the research community. Accepting this gift, since 2020 I have been making forecasts…
Biden-Harris policies and their consequences were no surprise to those paying attention
Peer Approval to Address Drug Shortages
02 Oct 2024 Leave a comment
in applied price theory, economics of regulation, health economics, politics - USA Tags: drug lags
Reuters: Mark Cuban’s Cost Plus Drug Company said…that it is working with the U.S. Food and Drug Administration to import and distribute penicillin in the country temporarily….Cuban’s Cost Plus will import Lentocilin brand penicillin powder marketed by Portugal-based Laboratórios Atral S.A. There are two remarkable items in the above passage. First, there is a shortage…
Peer Approval to Address Drug Shortages
The US Has Low Prices for Most Prescription Drugs
21 Sep 2024 Leave a comment
in applied price theory, economic history, health economics, industrial organisation Tags: drug lags
The US has high prices for branded drugs but it has some of the lowest prices for generic drugs in the world and generic drugs are 90% of prescriptions. I’ve been saying this for years but here is the latest study: U.S. prices for brand-name originator drugs were 422 percent of prices in comparison countries, […]
The US Has Low Prices for Most Prescription Drugs
Monkeypox and Medsafe
15 Sep 2024 Leave a comment
in applied price theory, applied welfare economics, comparative institutional analysis, economics of bureaucracy, economics of information, economics of regulation, health economics, politics - New Zealand, Public Choice Tags: drug lags, economics of pandemics
In a sane world, medicines and vaccines already approved by trustworthy overseas regulators would automatically be able to be used in New Zealand as well.New Zealand is not sane. But neither is anywhere else really on that standard. Other places are just faster than NZ in getting things approved, with more practicable pathways for expedited…
Monkeypox and Medsafe
The Pharmac Fiasco
09 Jul 2024 Leave a comment
in applied price theory, health economics, politics - New Zealand Tags: drug lags, patents and copyrights
If you don’t understand how things work you make foolish mistakes. To explain how the government got into its cancer drugs muddle, we need to explain first how New Zealand’s pharmaceutical purchasing system works. There is a parallel between Pharmac and the Reserve Bank of New Zealand. The Government sets the monetary policy framework with […]
The Pharmac Fiasco
Pharmac’s free ride won’t last forever
04 Jul 2024 Leave a comment
in applied price theory, comparative institutional analysis, health economics Tags: drug lags
Americans contribute disproportionately toward the pharmaceutical innovation from which we all benefit, but their tolerance for subsidising the rest of the world is on the wane… Eric Crampton writes If philosophy students remember one thing from their lectures on Immanuel Kant in undergraduate classes, it is his categorical imperative. It’s easy to remember […]
Pharmac’s free ride won’t last forever
Utopia, you are standing in it! 
Recent Comments